Dechta Pharmaceuticals 2017 final results
Strong financial performance:
Strong revenue growth of 28.3% at constant exchange rates (CER).
Solid revenue growth in Companion Animal Products (CAP), Food producing Animal Products (FAP), and Equine.
36.9% growth at CER in underlying operating profit.
Strong operational leverage and full year synergies from acquisitions lifts EBIT margin 140 bps to 22.6%.
Consistently strong cash conversion of 115.9%, driving Net Debt / underlying EBITDA leverage down from 2.0 to 1.4 times.
Underlying diluted EPS growth of 35.1%; increase in full year dividend to 21.44 pence.
